PRESS RELEASE published on 12/05/2025 at 18:34, 3 months 17 days ago VALNEVA Declaration of shares and voting rights: November 30, 2025 VALNEVA declares changes in shares and voting rights, including double voting rights granted on ordinary shares and transfer into bearer form Euronext Paris Voting Rights Shares Valneva Double Voting Rights
PRESS RELEASE published on 12/05/2025 at 18:34, 3 months 17 days ago VALNEVA Déclaration d’actions et de droits de vote : 30 novembre 2025 VALNEVA déclare des actions et des droits de vote, dont un passage en droit de vote double et un exercice d'options de souscription d'actions. Informations sur le siège social et le marché réglementé Euronext Paris Déclaration Droits De Vote Actions Valneva
BRIEF published on 12/03/2025 at 11:03, 3 months 19 days ago Valneva SE : Développements prometteurs dans le domaine du vaccin contre la maladie de Lyme Valneva SE Vaccin Contre La Maladie De Lyme Prévisions Du Marché Pfizer VLA15
BRIEF published on 12/03/2025 at 11:03, 3 months 19 days ago Valneva SE: Promising Developments in Lyme Disease Vaccine Valneva SE Lyme Disease Vaccine Market Forecast Pfizer VLA15
PRESS RELEASE published on 12/03/2025 at 10:58, 3 months 19 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation for Valneva SE, raising target price to €6.80. VLA15 vaccine progress and market potential analyzed Buy Recommendation Research Update Valneva SE Market Potential VLA15 Vaccine
BRIEF published on 11/04/2025 at 07:05, 4 months 18 days ago Valneva's Phase 1 Trial Yields Positive Results for Zika Vaccine Phase 1 Trial Valneva Immunogenicity Zika Vaccine Adjuvant
BRIEF published on 11/04/2025 at 07:05, 4 months 18 days ago L'essai de phase 1 de Valneva donne des résultats positifs pour le vaccin contre le Zika Valneva Immunogénicité Essai De Phase 1 Adjuvant Vaccin Contre Le Zika
PRESS RELEASE published on 11/04/2025 at 07:00, 4 months 18 days ago Valneva annonce des résultats positifs de Phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika Valneva annonce des résultats positifs de phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika, montrant une réponse immunitaire améliorée Valneva Immunitaire Phase 1 Vaccin Zika
PRESS RELEASE published on 11/04/2025 at 07:00, 4 months 18 days ago Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate Valneva SE reports positive Phase 1 trial results for VLA1601, its second-generation Zika vaccine candidate, showing improved immune response. Safety and immunogenicity demonstrated in trial Phase 1 Trial Valneva SE Safety Immunogenicity Zika Vaccine
BRIEF published on 10/09/2025 at 16:04, 5 months 13 days ago Bpifrance Crosses Threshold in the Capital of Valneva SE Stock Market Valneva SE Threshold Crossing Bpifrance Deposit Fund
Published on 03/20/2026 at 13:30, 2 days 9 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 10 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 10 hours 59 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 2 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 2 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 4 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 4 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 5 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 5 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
